Wei WT et al. showed that combination therapy with gemcitabine and evodiamine enhanced the anti-tumor efficacy by inhibiting the activities of phosphatidylinositol-3-kinase (PI3K), protein kinase B (AKT), cAMP-dependent protein kinase A (PKA), mammalian target of rapamycin (mTOR), and phosphatase and tensin homolog (PTEN), as well as the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and expression of NF-κB-regulated products in SW1990 human pancreatic cancer cells [8]. This evidence concerns the gene NFKB1 and pancreatic neoplasm.